Properties: this product is a white end of producing.
Pharmacological effects: this product is produced by genetic engineering mammalian cell growth hormone, can promote bone growth, increase myocardial contraction force; Promote protein synthesis, increase in nitrogen reserves; Increased fat oxidation decomposition and sugar dysplasia; Improve nutrient conversion rate; Adjust the immune system, enhance the immune defences.
Pharmacokinetic: about 80% after subcutaneous injection is absorbed, about 5 h after injection of the highest concentration of plasma, tl / 2 to 4 h.
Indications: for the children, adult growth hormone deficiency, Turner's syndrome, chronic renal insufficiency in children led to the growth of obstacles, after the surgery, trauma, high metabolic state (negative nitrogen balance), burns and sepsis.
Usage and dosage: intramuscular injection or hypodermic, dose depending on the disease. Dwarfism: 0.6 ~ 0.8 IU/kg per week, subcutaneous injection. Turner's syndrome: 1.0 IU/kg per week or per square meter surface 28 IU, subcutaneous injection. Chronic renal insufficiency to growth disorder in children: 1.0 IU/kg per week or per square meters surface 30 IU, subcutaneous injection. Negative nitrogen balance: 4 ~ 8 iu per day, 7, subcutaneous injection. Burns: 0.3 ~ 0.6 IU per day, 4 weeks, subcutaneous injection. Sepsis: 0.3 IU/kg per day. Adult growth hormone deficiencies: 0.25 IU/kg per week, 2 ~ 6 months.
